Testagen
- Category
- Bioregulators
- Administration routes
- InjectableOral
- Regulatory status
- Not FDA-approved
What it is
A synthetic four-amino-acid peptide marketed as a bioregulator for testosterone normalization and male reproductive support. The case rests on mechanistic and in vitro work from largely one research group, with essentially no independent human data behind the touted testosterone or thyroid effects. There is no formal human safety profile, and supply is unregulated research-grade product. Not an FDA-approved drug, with no established clinical indication.
Read Full recordStudied uses & evidence
Studied uses(6)
Testosterone normalization and male reproductive support
SpeculativeNo direct evidence in any species; testosterone effect is inferred, not measured, mechanism only.
Thyroid hormone normalization and thyroid gland structural restoration
LowConsistent animal studies show thyroid tissue and hormone recovery in birds; no human data yet.
Thymic immune tissue restoration
SpeculativeSingle animal study showed thymus tissue recovery on histology alone, no functional immune tests.
Evidence limits
- Evidence Level
- Preclinical
The clinical evidence for Testagen is extremely limited. Evidence for purified KEDG remains predominantly preclinical. Human reports concern commercial preparations, including Testoluten and an oral Testagen supplement studied in 36 men during 2010–2011. The latter compared adjunctive treatment with standard treatment and did not report blinding or chemical verification of pure KEDG. These reports do not establish efficacy or safety of injectable KEDG. The Testoluten report (Khavinson et al. 2006) involved 36 men aged 43-61, with 19 receiving active treatment, and showed a 26% testosterone increase over 10 days; it was not registered on any clinical trial registry, was not independently replicated, and was conducted entirely within Khavinson's research network. The remaining evidence is preclinical: avian models for thyroid effects (multiple studies by Kuznik et al.), cell culture for DNA/histone interaction (Fedoreyeva et al.), and in vitro rat testicular explant cultures. No Western clinical trials, no ClinicalTrials.gov registrations, and no independent verification of any clinical claims exist. The broader Khavinson peptide bioregulator program claims over 15 years of clinical use in Russia with favorable safety, but these results lack independent validation.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
No formal human safety profile established
HighAll safety data from a single research group without independent verification
HighResearch-grade product quality and purity concerns
HighPotential hormonal disruption
TheoreticalUnknown long-term effects of epigenetic modulation
TheoreticalInjection site reactions
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.